The Food and Drug Administration’s recent approval of the drug ibrutinib offers a major new option for patients with chronic lymphocytic leukemia (CLL) who tried at least one prior therapy, physicians say.
Tag Archive for Ibrutinib
Ann LaCasce, MD, a medical oncologist in the Dana-Farber/Brigham and Women’s Cancer Center Adult Lymphoma Program, answered a variety of questions about Hodgkin and non-Hodgkin lymphoma during a live web chat hosted by Dana-Farber last month.
Current lymphoma therapies are a far cry from the mustard gas used more than 50 years ago. More treatment options, including ones that may be more effective and less toxic, are being studied in ongoing clinical trials.